Ovarian yolk sac tumor in postmenopausal females: a report of five cases and a literature review

Purpose of investigation: Little is known regarding ovarian yolk sac tumor (YST) in postmenopausal females. The authors aimed to investigate the clinical features and prognosis of postmenopausal patients with ovarian YST. Materials and Methods: Five cases of ovarian YST in postmenopausal females were retrospectively reviewed. A MEDLINE search was performed to identify postmenopausal patients with ovarian YST Results: Four patients had Stage I or II disease (Stage IC, IIC, and IIB in one, two, and one patient, respectively), and one patient demonstrated an unclear stage. All five patients received surgery and postoperative chemotherapy. Four of the patients received chemotherapy with a regimen of bleomycin, etoposide, and cisplatin, and one patient received cisplatin as first-line chemotherapy. Of the four patients who had no residual tumors at the initial surgery, three patients recurred at 3.0, 8.5, and 9.0 months after diagnosis, respectively. The three patients who had recurrence lived for an additional time of 21.8, 10.0, and 11.5 months after relapse. Four patients died of the disease at 30.8, 18.5, 14.5, and 8.5 months after diagnosis; one patient survived without tumor at 40.0 months. The three-year survival was 20.0%. Of the 12 cases identified from the literature, the three-year survival was 34.0%. Conclusion: The clinical features of ovarian YST in postmenopausal females, such as stage distribution, were similar compared to young patients. Postmenopausal patients with ovarian YST may have a worse prognosis compared to young patients.

Ovarian yolk sac tumor; Postmenopausal; AFP.

[1] Dallenbach P., Bonnefoi H., Pelte M.F.,Vlastos G.: “Yolk sac tumours of the ovary: an update”. Eur. J. Surg. Oncol., 2006, 32, 1063.

[2] Quirk J.T., Natarajan N., Mettlin C.J.: “Age-specific ovarian cancer incidence rate patterns in the United States”. Gynecol. Oncol., 2005, 99, 248.

[3] Kurman R.J., Norris H.J.: “Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases”. Cancer, 1976, 38, 2404.

[4] de La Motte R.T., Pautier P., Rey A., Duvillard P., Kerbrat P., Troalen F., et al.: “Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases”. Eur. J. Cancer, 2011, 47, 175.

[5] de La Motte R.T., Pautier P., Duvillard P., Rey A., Morice P.,Haie- Meder C., et al.: “Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor”. Ann. Oncol., 2008, 19, 1435.

[6] Feldman D.R., Voss M.H., Jacobsen E.P., Jia X., Suarez J.A.,Turkula S., et al.: "Clinical features, presentation, and tolerance of platinumbased chemotherapy in germ cell tumor patients 50 years of age and older". Cancer, 2013, 119, 2574.

[7] Lange S., Livasy C.,Tait D.L.: “Endodermal sinus tumor of the ovary in an 86 year old woman”. Gynecol. Oncol. Case Rep., 2012, 2, 65.

[8] Filiz G., Ozuysal S., Bilgin T.: “Ovarian endodermal sinus tumor in a 76-year-old woman”. J. Obstet. Gynaecol. Res., 2003, 29, 309.

[9] Oh C., Kendler A., Hernandez E.: “Ovarian endodermal sinus tumor in a postmenopausal woman”. Gynecol Oncol., 2001, 82, 392.

[10] Arai T., Kitayama Y., Koda K.: “Ovarian mucinous cystadenocarcinoma with yolk sac tumor in a 71-year-old woman”. Int. J. Gynecol. Pathol., 1999, 18, 277.

[11] Horiuchi A., Osada R., Nakayama K., Toki T., Nikaido T., Fujii S.: “Ovarian yolk sac tumor with endometrioid carcinoma arising from endometriosis in a postmenopausal woman, with special reference to expression of alpha-fetoprotein, sex steroid receptors, and p53”. Gynecol. Oncol., 1998, 70, 295.

[12] Nogales F.F., Bergeron C., Carvia R.E., Alvaro T.,Fulwood H.R.: "Ovarian endometrioid tumors with yolk sac tumor component, an unusual form of ovarian neoplasm. Analysis of six cases". Am J Surg Pathol., 1996,20, 1056.

[13] Kinoshita K.: “A 62-year-old woman with endodermal sinus tumor of the ovary”. Am. J. Obstet. Gynecol., 1990, 162, 760.

[14] Mazur M., Talbot W. Jr. ,Talerman A.: “Endodermal sinus tumor and mucinous cystadenofibroma of the ovary. Occurrence in an 82- yearold woman”. Cancer, 1988, 62, 2011.

[15] Brown J.R., Green J.D.: “Yolk sac carcinoma”. South Med. J., 1976, 69, 728.

[16] Talerman A., Haije W.G., Baggerman L.: “Serum alphafetoprotein (AFP) in diagnosis and management of endodermal sinus (yolk sac) tumor and mixed germ cell tumor of the ovary”. Cancer, 1978, 41, 272.

[17] Kumar S., Shah J.P., Bryant C.S., Imudia A.N., Cote M.L.,Ali-Fehmi R., et al.: “The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary”. Gynecol. Oncol., 2008, 110, 125.

[18] Nawa A., Obata N., Kikkawa F., Kawai M., Nagasaka T., Goto S., et al.: “Prognostic factors of patients with yolk sac tumors of the ovary”. Am. J. Obstet. Gynecol., 2001, 184, 1182.

[19] Tong X., You Q., Li L., Cai L., Wang C., Zheng J.: “Prognostic factors of patients with ovarian yolk sac tumors: a study in Chinese patients”. Onkologie, 2008, 31, 679.

[20] Liu Q., Ding X., Yang J., Cao D., Shen K., Lang J., et al.: “The significance of comprehensive staging surgery in malignant ovarian germ cell tumors”. Gynecol. Oncol., 2013, 131, 551.

[21] Kawai M., Kano T., Furuhashi Y., Mizuno K., Nakashima N., Hattori S.E., et al.: “Prognostic factors in yolk sac tumors of the ovary. A clinicopathologic analysis of 29 cases”. Cancer, 1991, 67, 184.

[22] Cicin I., Saip P., Guney N., Eralp Y., Ayan I., Kebudi R., et al.: “Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 146, 210.

[23] Kondagunta G.V., Bacik J., Donadio A., Bajorin D., Marion S., Sheinfeld J., et al.: "Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors”. J. Clin. Oncol., 2005, 23, 6549.

[24] Einhorn L.H., Williams S.D., Chamness A., Brames M.J., Perkins S.M., Abonour R.: “High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors”. N. Engl. J. Med., 2007, 357, 340.

[25] Jeyakumar A., Chalas E., Hindenburg A.: “Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor”. Gynecol. Oncol., 2001, 82, 578.